<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">52946</article-id><article-id pub-id-type="doi">10.7554/eLife.52946</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Human Biology and Medicine</subject></subj-group></article-categories><title-group><article-title>Identification of drug modifiers for RYR1 related myopathy using a multi-species discovery pipeline</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-163773"><name><surname>Volpatti</surname><given-names>Jonathan R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-163774"><name><surname>Endo</surname><given-names>Yukari</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-178893"><name><surname>Knox</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-163775"><name><surname>Groom</surname><given-names>Linda</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-163776"><name><surname>Brennan</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-163777"><name><surname>Noche</surname><given-names>Ramil</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-103214"><name><surname>Zuercher</surname><given-names>William J</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-163779"><name><surname>Roy</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-36449"><name><surname>Dirksen</surname><given-names>Robert T</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3182-1755</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-13465"><name><surname>Dowling</surname><given-names>James J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3984-4169</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Program in Genetics and Genome Biology</institution>, <institution>The Hospital for Sick Children</institution>, <addr-line><named-content content-type="city">Toronto</named-content></addr-line>, <country>Canada</country></aff><aff id="aff2"><institution content-type="dept">Department of Molecular Genetics</institution>, <institution>University of Toronto</institution>, <addr-line><named-content content-type="city">Toronto</named-content></addr-line>, <country>Canada</country></aff><aff id="aff3"><institution content-type="dept">Department of Pharmacology</institution>, <institution>University of Rochester</institution>, <addr-line><named-content content-type="city">Rochester</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">UNC Eshelman School of Pharmacy</institution>, <institution>University of North Carolina at Chapel Hill</institution>, <addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Molecular Genetics</institution>, <institution>University of Toronto</institution>, <addr-line><named-content content-type="city">Toronto</named-content></addr-line>, <country>Canada</country></aff><aff id="aff6"><institution content-type="dept">Department of Pharmacology and Physiology</institution>, <institution>University of Rochester School of Medicine and Dentistry</institution>, <addr-line><named-content content-type="city">Rochester</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-21593"><name><surname>Mumm</surname><given-names>Jeff S</given-names></name><role>Reviewing editor</role><aff><institution>Johns Hopkins University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>james.dowling@sickkids.ca</email> (JD);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>30</day><month>03</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e52946</elocation-id><history><date date-type="received"><day>22</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>29</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement>Â© 2020, Volpatti et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Volpatti et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-52946-v1.pdf"/><abstract><p>Ryanodine receptor type I-related myopathies (RYR1-RMs) are a common group of childhood muscle diseases associated with severe disabilities and early mortality for which there are no available treatments. The goal of this study is to identify new therapeutic targets for RYR1-RMs. To accomplish this, we developed a discovery pipeline using nematode, zebrafish, and mammalian cell models. We first performed large-scale drug screens in <italic>C. elegans</italic> which uncovered 74 hits. Targeted testing in zebrafish yielded positive results for two p38 inhibitors. Using mouse myotubes, we found that either pharmacological inhibition or siRNA silencing of p38 impaired caffeine-induced Ca<sup>2+</sup> release from wild type cells while promoting intracellular Ca<sup>2+</sup> release in <italic>Ryr1</italic> knockout cells. Lastly, we demonstrated that p38 inhibition blunts the aberrant temperature-dependent increase in resting Ca<sup>2+</sup> in myotubes from an RYR1-RM mouse model. This unique platform for RYR1-RM therapy development is potentially applicable to a broad range of neuromuscular disorders.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>C. elegans</italic></kwd><kwd>Mouse</kwd><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005202</institution-id><institution>Muscular Dystrophy Association</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Dirksen</surname><given-names>Robert T</given-names></name><name><surname>Dowling</surname><given-names>James J</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>RYR1 Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Dirksen</surname><given-names>Robert T</given-names></name><name><surname>Dowling</surname><given-names>James J</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>363863</award-id><principal-award-recipient><name><surname>Dirksen</surname><given-names>Robert T</given-names></name><name><surname>Dowling</surname><given-names>James J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All zebrafish experiments were performed in accordance with all relevant ethical regulations, specifically following the policies and guidelines of the Canadian Council on Animal Care and an institutionally reviewed and approved animal use protocol (#41617). No additional ethical approval was required for our experiments with the invertebrate nematode worm C. elegans.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source files are available for all figures.</p></sec><supplementary-material><ext-link xlink:href="elife-52946-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>